Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials.
The epidemiology and treatment of ALS : focus on the heterogeneity of the disease and critical appraisal of therapeutic trials / E. Beghi, A. Chiò, P. Couratier, J. Esteban, O. Hardiman, G. Lagroscino, A. Millul, D. Mitchell, P.M. Preux, E. Pupillo, Z. Stevic, R. Swingler, B.J. Traynor, L. Van Den Berg, J.H. Veldink, S. Zoccollella, V. Silani, EURALS Consortium. - In: AMYOTROPHIC LATERAL SCLEROSIS. - ISSN 1748-2968. - 12:1(2011), pp. 1-10.
The epidemiology and treatment of ALS : focus on the heterogeneity of the disease and critical appraisal of therapeutic trials
V. SilaniPenultimo
;
2011
Abstract
Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest extent. Explanations for the negative results of therapeutic trials include a likely heterogeneity, both in disease susceptibility and pathogenic mechanisms, and faulty methodology of clinical trials. Further understanding of these factors will lead to improvements in patient stratification, and in the design of future clinical trials.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
